AstraZeneca India's anti-diabetic drug dapagliflozin cleared for CKD treatment
AstraZeneca India's anti-diabetic drug receives approval for CKD treatment AstraZeneca India's anti-diabetic drug receives approval for CKD treatment 08 February 2021 | News AstraZeneca’s dapagliflozin is the first medicine in SGLT-2i class to move into a new disease area by demonstrating efficacy and safety data for the treatment of patients with chronic kidney disease (CKD) Source credit: Shutterstock AstraZeneca India (AstraZeneca Pharma India Limited), a leading science-led biopharmaceutical company, announced that they have received marketing authorisation for their anti-diabe...
Source: biospectrumindia.com